image skincare vol.u.lift glp-1 4d skin rebound complex Introducing VOL.U.LIFT™ featuring Complex, First-to-market innovation to address the visible side effects of GLP-1-induced rapid weight loss on facial skin., This first-to-market crepey skin IMAGE VOL.U.LIFT™ GLP-1 4D Skin
Description
Beyond lowering HbA1c levels, these medications often reduce cardiovascular risks and may even slow the progression of kidney disease in people with diabetes
They target the body and mind simultaneously, helping to reduce a primary cause of weight gain: a strong appetite that leads to overeating
Because of this, the drug is a good choice for people with diabetes and for anyone looking to lower their body weight
Fudim M, et al
Viking Pharmaceuticals is also developing a drug that activates both the GLP-1 and GIP receptors
43% cover Food and Drug Adminstration-approved weight loss medications and 28% may in the next one to two years
